The proxy fight is low-intensity given the dissident's small stake and the board's recent addition of a qualified independent director. The outcome likely favors management's slate. Monitor the annual meeting date and any further dissident filings for escalation.
Price Chart
Executive Summary
Vaxart filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting, facing a contested director election from stockholder Daniel P. Houle, who nominated himself and two others. The filing identifies the board's six nominees and four executive officers as participants in the solicitation, reiterating the company's recommendation to vote FOR its slate. The dissident holds ~0.7% of shares, and the board recently added an independent director with biotech experience, strengthening its position.
Key Facts
- Vaxart filed DEFA14A soliciting proxies for the 2026 Annual Meeting with a contested director election.
- Stockholder Daniel P. Houle nominated himself and two others as dissident candidates.
- The board unanimously recommends voting FOR its six nominees, citing the dissidents' lack of relevant biotech experience and small ownership stake (~0.7%).
- The board recently appointed James B. Breitmeyer, M.D., Ph.D., a veteran biotech executive, as an independent director.
- Participants in the solicitation include all six board nominees and four executive officers.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- Dissident could gain traction if institutional investors are dissatisfied with Vaxart's clinical progress or cash runway.
- Proxy contest could distract management from pipeline execution.
- Low probability of dissident slate winning given ownership disparity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-059239 |
| Document: 0001213900-26-059239-index-headers.html | 0001213900-26-059239 |
| Document: 0001213900-26-059239-index.html | 0001213900-26-059239 |
| Document: 0001213900-26-059239.txt | 0001213900-26-059239 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 28, 2026 9w ago | 8-K | $0.4800 $0.5000 | ▲ +4.17% | ▲ +0.79% | $0.4301 (−10.40%) |
Jul 7, 2026 12w ago | 8-K | $0.5500 $0.6000 | ▲ +9.09% | ▲ +5.93% | $0.4301 (−21.80%) |
Jul 6, 2026 12w ago | DEFA14A | $0.6200 $0.5900 | ▼ −4.84% | ▼ −5.69% | $0.4301 (−30.63%) |
Jul 2, 2026 13w ago | DEFA14A | $0.6400 $0.5490 | ▼ −14.22% | ▼ −14.52% | $0.4301 (−32.80%) |
Jul 2, 2026 13w ago | 8-K | $0.6400 $0.5200 | ▼ −18.75% | ▼ −18.34% | $0.4301 (−32.80%) |
Jun 26, 2026 13w ago | DEFA14A | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4301 (−24.54%) |
Jun 26, 2026 13w ago | DEFA14A | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4301 (−24.54%) |
Jun 26, 2026 13w ago | 8-K | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4301 (−24.54%) |
Jun 16, 2026 15w ago | DEFA14A | $0.5600 $0.5300 | ▼ −5.36% | ▼ −6.21% | $0.4301 (−23.20%) |
Jun 8, 2026 16w ago | DEFA14A | $0.5800 $0.5502 | ▼ −5.14% | ▼ −6.53% | $0.4301 (−25.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access